Developer docs
API playgroundTry for free, no card

Search company profiles

AutoPhagyGO

Full company profile

uuid0002ypd

Namestring
AutoPhagyGO
Legal namestring
株式会社AutoPhagyGO
Websiteurl
autophagygo.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

AutoPhagyGO Inc. (株式会社AutoPhagyGO) is a privately held Japanese biotechnology company founded in June 2019 as a university-originated startup from Osaka University, headquartered in the Osaka University Industry-Academia Co-creation Building A in Suita City, Osaka. The company is built on the autophagy research of co-founder and technical advisor Professor Tamotsu Yoshimori, a globally ranked researcher who co-discovered the LC3 autophagosome marker and identified the Rubicon protein as an autophagy brake. AutoPhagyGO develops and commercializes autophagy-activating products and services aimed at healthspan extension and age-related disease prevention, serving two primary segments: health-conscious consumers via proprietary supplements sold on Amazon Japan, and food/pharmaceutical/cosmetics enterprises via co-development agreements, contract autophagy activity measurement services, and licensing of ingredients such as urolithin A.

The company's commercial portfolio includes two proprietary consumer SKUs — Awa Bancha Autophagy 100 tablets (launched April 2025) and Awa Bancha Autophagy Tea (launched July 2025) — both based on a traditional Tokushima fermented tea extract. It also generates revenue through co-developed products including Autophagy Habit PLATINUM with UHA Mikakuto and Urolithin Capsule with Kyowa, plus exclusive distribution of autophagy activity evaluation services through Human Metabolome Technologies (HMT). Its enterprise partnerships span domestic investors and customers (UHA Mikakuto, Kobayashi Pharmaceutical, Kyowa, ENEOS, Euglena, Shionogi, Medical Corporation Sogakai) and international research collaborators (Oxford Healthspan, Korean ORGASIS).

AutoPhagyGO has cumulatively raised approximately ¥392M across four funding rounds between 2020 and 2023 (registered capital ¥28.93M), maintains a 1–10 employee footprint, and operates as an open-innovation platform with founding participation in the Japan Autophagy Consortium. In 2025 it advanced to the semifinals of the $101M XPRIZE Healthspan competition as 'Team 10 years Rewind with AUTOPHAGY' alongside Curationz and Dentsu, and has won multiple innovation awards including the 2023 Healthcare Venture Award Academic Society Prize.

Short descriptiontext

AutoPhagyGO is a privately held Osaka University spin-out that develops autophagy-activating health supplements (Awa Bancha line) and contract autophagy measurement services for food, pharmaceutical, and cosmetics enterprises, leveraging co-founder Tamotsu Yoshimori's foundational autophagy research to target healthspan extension and age-related disease prevention.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSuita, Japan
HQ citystring
Suita
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autophagy research services, longevity dietary supplements, healthspan extension products, biotech contract research, functional food development
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Longevity and Healthspan Biotechnology
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Consumer Health Supplement Sales
TypeOne Time License
Description

Direct-to-consumer sales of proprietary autophagy-activating supplements — Awa Bancha Autophagy 100 tablets and Awa Bancha Autophagy Tea — via Amazon Japan, own e-commerce website, and potentially through UHA Mikakuto's health/beauty online store.

autophagygo.com
2Autophagy Measurement Contract Services
TypeProfessional Services
Description

Fee-for-service autophagy activity measurement contracts with enterprise clients (food, pharmaceutical, cosmetics companies) seeking to screen natural ingredients for autophagy activation. Described as exclusively available through Human Metabolome Technologies (HMT) partnership.

autophagygo.com
3Co-Development and Licensing (B2B)
TypeLicensing Royalties
Description

Joint product development arrangements with food, pharmaceutical, and cosmetics companies — including co-development agreements with UHA Mikakuto (Autophagy Habit PLATINUM, Urolithin Capsule), Kyowa (Urolithin Capsule via fracora), Shionogi Pharma, and others — generating revenue through co-developed product royalties and licensing.

autophagygo.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
Pricing details2 tiers
1Awa Bancha Autophagy 100 — 30-tablet supplement pack
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Product dimensions: 10 x 90 x 150 mm; package: zippered aluminum pouch; contains Awa Bancha extract powder, reduced maltose syrup, cellulose, stearic acid calcium, HPC, fine particulate silica. Available on Amazon Japan.

autophagygo.com
2Awa Bancha Autophagy Tea — 10 tea bag pack, 100% natural caffeine-free tea
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Weight: 20.0g; package: zippered paper pouch; made from Awa Bancha (caffeine-free). Available on Amazon Japan.

autophagygo.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 2 records shown
1阿波晩茶オートファジー100™
Description

Awa Bancha concentrated extract supplement for health longevity, certified by Japan Autophagy Consortium.

autophagygo.com
+1 more record
Core offering1 text field

AutoPhagyGO develops, brands, and sells autophagy-activating health supplements derived from Awa Bancha (a traditional fermented tea from Tokushima Prefecture), including Awa Bancha Autophagy 100 tablets and Awa Bancha Autophagy Tea. The company also provides contract autophagy activity measurement services to food, pharmaceutical, and cosmetics companies through an exclusive partnership with Human Metabolome Technologies, and engages in joint product co-development with industry partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Rubicon knockout extends lifespan by 1.2x in model organisms (nematodes, fruit flies)
+2 more records
Product overview1 text field

AutoPhagyGO is a university-born venture company focused on autophagy research, led by Professor Tamotsu Yoshimori (Osaka University). The company operates as a health technology firm offering proprietary dietary supplements and conducting autophagy activity measurement services. The product portfolio consists of two proprietary products—Awa Bancha Autophagy 100™ (tablet supplement) and Awa Bancha Autophagy Tea™ (tea bag)—both featuring Awa Bancha, a traditional fermented tea from Tokushima Prefecture. Additional co-developed products include Autophagy Habit PLATINUM and Urolithin Capsule with partner companies. The company also provides autophagy activity evaluation services to partner enterprises for ingredient screening and research purposes.

Product and service5 records
1Awa Bancha Autophagy 100 (阿波晩茶オートファジー100)
CategoryConsumer Health Supplement
Description

Proprietary tablet supplement containing concentrated Awa Bancha (traditional Japanese fermented tea from Tokushima Prefecture) extract, certified by the Japan Autophagy Consortium for autophagy-activating performance. Targeted at health-conscious consumers seeking healthspan and longevity support.

2Awa Bancha Autophagy Tea (阿波晩茶オートファジーティー)
CategoryConsumer Health Beverage
Description

Proprietary caffeine-free tea bag product made from 100% natural Awa Bancha tea leaves, designed for daily consumption to support autophagy as part of consumer health habits.

3Autophagy Habit PLATINUM (オートファジー習慣PLATINUM)
CategoryCo-developed Functional Food Supplement
Description

Co-developed supplement with UHA Mikakuto containing urolithin A and resveratrol, both food ingredients recognized for autophagy activity. Sold through UHA Mikakuto's health/beauty e-commerce channel.

4Urolithin Capsule (ウロリチンカプセル)
CategoryCo-developed Functional Food Supplement
Description

Co-developed capsule product with Kyowa Co., Ltd. containing urolithin A (a gut bacteria metabolite of ellagic acid from pomegranates and berries), sold under the fracora beauty brand via fracora's official e-commerce site.

5Autophagy Activity Measurement Contract Service
CategoryBiotech Contract Research Service
Description

Contract research service quantifying autophagy activity at cell, tissue, and organism levels for enterprise clients (food, pharmaceutical, cosmetics companies) screening natural compounds for autophagy-activating properties. Distributed exclusively through Human Metabolome Technologies (HMT).

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
1Curationz Co., Ltd. (キュレーションズ株式会社)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-28
Description

AutoPhagyGO and Curationz Co., Ltd. formed a partnership for the XPRIZE Healthspan competition as part of 'Team 10 years Rewind with AUTOPHAGY.' Curationz contributes digital technology and health domain expertise. The team advanced to the semifinals of the $101M longevity competition focused on reversing biological age by 10–20 years.

autophagygo.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-28
Description

Dentsu Inc. joined 'Team 10 years Rewind with AUTOPHAGY' for the XPRIZE Healthspan competition, contributing to the team's outreach and industrialization efforts for autophagy-based longevity solutions.

3Medical Corporation Sogakai (銀座アイグラッドクリニック / 医療法人社団創雅会)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

AutoPhagyGO signed an MOU with Medical Corporation Sogakai (operator of Ginza IGrad Clinic) to jointly develop and promote new doctor's cosmetics leveraging autophagy technology, aiming to contribute to a healthy longevity society through autophagy technology social implementation.

autophagygo.com
4Japanese Autophagy Consortium (了一般社团法人 日本オートファジーコンソーシアム)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-08-28
Description

APGO is a participating member and co-organizer of the Japan Autophagy Consortium. CEO Miwako Ishido served as Representative Director (2020–2023) and continues as Director (2024–present). APGO co-hosts consortium symposiums and events.

autophagygo.com
5Curationz Co., Ltd. (MOU)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-31
Description

MOU signed for 'Proactive AgeTech' — combining cell science with digital technology to develop solutions that effectively suppress and restore cellular aging. Partnership centered on XPRIZE HEALTHSPAN competition entry.

autophagygo.com
6ORGASIS Corp. (Korea)
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2024-03-22
Description

AutoPhagyGO signed an MOU with Korean venture company ORGASIS Corp. to strengthen and expand R&D capabilities. The partnership focuses on collaborative research in autophagy-related drug discovery, and new material R&D in food and cosmetics fields.

autophagygo.com
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

Joint research contract signed November 1, 2023 to evaluate the correlation between autophagy activity and the therapeutic effects of UC-MSCs (umbilical cord-derived mesenchymal stem cells) for age-related diseases, and to explore biomarkers for clinical applications.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-08-28
Description

Business partnership agreement for exclusive distribution of autophagy activity evaluation services. HMT provides cutting-edge metabolomics analysis services and functional ingredient development support. HMT serves as the exclusive service desk for APGO's autophagy measurement offerings, leveraging HMT's extensive sales network.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-10-25
Description

APGO participates in the JST COI-NEXT 'Regional Co-Creation Type' project led by Muroran Institute of Technology. Focus on creating new food value through the 'Asir-Toyta' (healthy diet) co-creation hub.

10Customer Value Co-Creation Do (顧客価値共創堂)
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2022-03-01
Description

Consultant services agreement to support APGO's role as an open innovation platform, helping accelerate industry adoption of autophagy research findings and sustainable enterprise value growth.

autophagygo.com
11Japan Autophagy Consortium (第一回日本オートファジーコンソーシアム)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-02-04
Description

APGO participates as founding member and co-organizer of the Japan Autophagy Consortium, established to promote autophagy research applications in industry and academia.

autophagygo.com
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2022-01-13
Description

Joint research to investigate the effects of Euglena-derived ingredients on autophagy. APGO provides autophagy measurement capabilities while Euglena provides its proprietary microalgae ingredient research.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2022-01-13
Description

Commissioned research agreement for ENEOS-developed materials and their effects on autophagy modulation. APGO conducts autophagy activity measurement for ENEOS ingredient candidates.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2022-01-13
Description

Collaboration to conduct autophagy activity tests in mammalian cells. Jointly aiming to leverage autophagy function for healthspan improvement through scientific validation of longevity ingredients.

15Kumamoto University Global Natural Products Research Center
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-12-21
Description

Joint research with Associate Professor Go Shuto of Kumamoto University to verify the effects of autophagy activation on healthspan extension. Aims to develop autophagy-activating ingredient formulations for healthy longevity.

autophagygo.com
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2021-03-15
Description

Joint research to identify ingredients that modulate autophagy activity. Target is to develop new products with preventive and improving effects on age-related symptoms.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Timeline Nutrition commercialises Mitopure (urolithin A) — the same autophagy-activating ingredient that AutoPhagyGO co-developed with Kyowa/fracora. It is the closest direct competitor on consumer autophagy supplements globally.

TypeDirect peer
Description

US-based direct-to-consumer longevity supplements brand built on academic research (e.g., Basis with NR/NMN). Same playbook as AutoPhagyGO: science-led IP, premium branded SKUs, longevity audiences.

3ChromaDex
TypeDirect peer
Description

Ingredient supplier (Niagen/NMN) and longevity platform with consumer and B2B channels. Comparable to AutoPhagyGO in leveraging proprietary cellular-health IP for both ingredient licensing and consumer products.

TypeDirect peer
Description

Japanese metabolomics services and exclusive distribution partner for AutoPhagyGO's autophagy measurement service. Operates an overlapping B2B life-science services business and accesses many of the same Japanese pharma/food clients.

TypeEmerging player
Description

Clinical-stage longevity biotech developing senolytics to clear senescent cells (similar mechanism logic to APGO's autophagy activation). Same fundamental 'aging as a treatable biological state' thesis, different modality.

TypeBroad incumbent
Description

Alphabet-backed longevity R&D organisation focused on aging biology and age-related disease therapeutics. Operates at vastly larger scale but pursues the same overarching goal of translating cellular maintenance mechanisms into healthspan gains.

TypeEmerging player
Description

Vet-focused longevity biotech pursuing FDA pathway for lifespan extension drugs. Highly comparable to APGO in proving that cellular-age biology can produce regulatory-grade healthspan interventions, but on the veterinary side.

TypeOthers
Description

Japanese confectionery and health-foods company that is a multi-round investor, co-developer of Autophagy Habit PLATINUM, and a strategic channel partner for AutoPhagyGO products in Japan.

9Kobayashi Pharmaceutical
TypeOthers
Description

Major Japanese OTC/health-goods manufacturer, second-round investor in AutoPhagyGO and co-development partner. Comparable as a Japan-headquartered health-products commercialiser that has invested behind the autophagy thesis.

TypeRegional player
Description

Japanese bio-ingredient company (microalgae/paramylon) with an active autophagy joint-research agreement with AutoPhagyGO. Comparable as a Japan-based biotech commercialising functional food ingredients with university-derived IP.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AutoPhagyGO

Longevity and Healthspan Biotechnologyautophagygo.com

AutoPhagyGO is a privately held Osaka University spin-out that develops autophagy-activating health supplements (Awa Bancha line) and contract autophagy measurement services for food, pharmaceutical, and cosmetics enterprises, leveraging co-founder Tamotsu Yoshimori's foundational autophagy research to target healthspan extension and age-related disease prevention.

What AutoPhagyGO does

AutoPhagyGO Inc. (株式会社AutoPhagyGO) is a privately held Japanese biotechnology company founded in June 2019 as a university-originated startup from Osaka University, headquartered in the Osaka University Industry-Academia Co-creation Building A in Suita City, Osaka. The company is built on the autophagy research of co-founder and technical advisor Professor Tamotsu Yoshimori, a globally ranked researcher who co-discovered the LC3 autophagosome marker and identified the Rubicon protein as an autophagy brake. AutoPhagyGO develops and commercializes autophagy-activating products and services aimed at healthspan extension and age-related disease prevention, serving two primary segments: health-conscious consumers via proprietary supplements sold on Amazon Japan, and food/pharmaceutical/cosmetics enterprises via co-development agreements, contract autophagy activity measurement services, and licensing of ingredients such as urolithin A.

The company's commercial portfolio includes two proprietary consumer SKUs — Awa Bancha Autophagy 100 tablets (launched April 2025) and Awa Bancha Autophagy Tea (launched July 2025) — both based on a traditional Tokushima fermented tea extract. It also generates revenue through co-developed products including Autophagy Habit PLATINUM with UHA Mikakuto and Urolithin Capsule with Kyowa, plus exclusive distribution of autophagy activity evaluation services through Human Metabolome Technologies (HMT). Its enterprise partnerships span domestic investors and customers (UHA Mikakuto, Kobayashi Pharmaceutical, Kyowa, ENEOS, Euglena, Shionogi, Medical Corporation Sogakai) and international research collaborators (Oxford Healthspan, Korean ORGASIS).

AutoPhagyGO has cumulatively raised approximately ¥392M across four funding rounds between 2020 and 2023 (registered capital ¥28.93M), maintains a 1–10 employee footprint, and operates as an open-innovation platform with founding participation in the Japan Autophagy Consortium. In 2025 it advanced to the semifinals of the $101M XPRIZE Healthspan competition as 'Team 10 years Rewind with AUTOPHAGY' alongside Curationz and Dentsu, and has won multiple innovation awards including the 2023 Healthcare Venture Award Academic Society Prize.

AutoPhagyGO firmographics

Firmographics
Name
AutoPhagyGO
Legal name
株式会社AutoPhagyGO
Website
https://autophagygo.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
AutoPhagyGO is a privately held Osaka University spin-out that develops autophagy-activating health supplements (Awa Bancha line) and contract autophagy measurement services for food, pharmaceutical, and cosmetics enterprises, leveraging co-founder Tamotsu Yoshimori's foundational autophagy research to target healthspan extension and age-related disease prevention.
Ownership category
akta.pro rank

Where AutoPhagyGO is headquartered

Location

Headquarters

HQ city
Suita
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

AutoPhagyGO business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Consumer Health Supplement Sales: Direct-to-consumer sales of proprietary autophagy-activating supplements — Awa Bancha Autophagy 100 tablets and Awa Bancha Autophagy Tea — via Amazon Japan, own e-commerce website, and potentially through UHA Mikakuto's health/beauty online store.
  2. Autophagy Measurement Contract Services: Fee-for-service autophagy activity measurement contracts with enterprise clients (food, pharmaceutical, cosmetics companies) seeking to screen natural ingredients for autophagy activation. Described as exclusively available through Human Metabolome Technologies (HMT) partnership.
  3. Co-Development and Licensing (B2B): Joint product development arrangements with food, pharmaceutical, and cosmetics companies — including co-development agreements with UHA Mikakuto (Autophagy Habit PLATINUM, Urolithin Capsule), Kyowa (Urolithin Capsule via fracora), Shionogi Pharma, and others — generating revenue through co-developed product royalties and licensing.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAwa Bancha Autophagy 100 — 30-tablet supplement pack
Unit PricingPay-as-you-goAwa Bancha Autophagy Tea — 10 tea bag pack, 100% natural caffeine-free tea

Go-to-market motion4 records

Distribution channels4 records

Marketing channels8 records

AutoPhagyGO product offering

Product offering

Core offering

AutoPhagyGO develops, brands, and sells autophagy-activating health supplements derived from Awa Bancha (a traditional fermented tea from Tokushima Prefecture), including Awa Bancha Autophagy 100 tablets and Awa Bancha Autophagy Tea. The company also provides contract autophagy activity measurement services to food, pharmaceutical, and cosmetics companies through an exclusive partnership with Human Metabolome Technologies, and engages in joint product co-development with industry partners.

Product overview

AutoPhagyGO is a university-born venture company focused on autophagy research, led by Professor Tamotsu Yoshimori (Osaka University). The company operates as a health technology firm offering proprietary dietary supplements and conducting autophagy activity measurement services. The product portfolio consists of two proprietary products—Awa Bancha Autophagy 100™ (tablet supplement) and Awa Bancha Autophagy Tea™ (tea bag)—both featuring Awa Bancha, a traditional fermented tea from Tokushima Prefecture. Additional co-developed products include Autophagy Habit PLATINUM and Urolithin Capsule with partner companies. The company also provides autophagy activity evaluation services to partner enterprises for ingredient screening and research purposes.

Differentiator

Problem solved

Functional benefit

Brands

  • 阿波晩茶オートファジー100™: Awa Bancha concentrated extract supplement for health longevity, certified by Japan Autophagy Consortium.
  • 阿波晩茶オートファジーティー™

Products and services

  • Awa Bancha Autophagy 100 (阿波晩茶オートファジー100) Proprietary tablet supplement containing concentrated Awa Bancha (traditional Japanese fermented tea from Tokushima Prefecture) extract, certified by the Japan Autophagy Consortium for autophagy-activating performance. Targeted at health-conscious consumers seeking healthspan and longevity support.
  • Awa Bancha Autophagy Tea (阿波晩茶オートファジーティー) Proprietary caffeine-free tea bag product made from 100% natural Awa Bancha tea leaves, designed for daily consumption to support autophagy as part of consumer health habits.
  • Autophagy Habit PLATINUM (オートファジー習慣PLATINUM) Co-developed supplement with UHA Mikakuto containing urolithin A and resveratrol, both food ingredients recognized for autophagy activity. Sold through UHA Mikakuto's health/beauty e-commerce channel.
  • Urolithin Capsule (ウロリチンカプセル) Co-developed capsule product with Kyowa Co., Ltd. containing urolithin A (a gut bacteria metabolite of ellagic acid from pomegranates and berries), sold under the fracora beauty brand via fracora's official e-commerce site.
  • Autophagy Activity Measurement Contract Service Contract research service quantifying autophagy activity at cell, tissue, and organism levels for enterprise clients (food, pharmaceutical, cosmetics companies) screening natural compounds for autophagy-activating properties. Distributed exclusively through Human Metabolome Technologies (HMT).

Quantifiable outcome

  • Rubicon knockout extends lifespan by 1.2x in model organisms (nematodes, fruit flies)
  • +2 more outcomes

Companies that use AutoPhagyGO

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

AutoPhagyGO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AutoPhagyGO partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core, major, secondary and minor.

  • Curationz Co., Ltd. (キュレーションズ株式会社)coreStrategic or Co-development Partner · 28 November 2025AutoPhagyGO and Curationz Co., Ltd. formed a partnership for the XPRIZE Healthspan competition as part of 'Team 10 years Rewind with AUTOPHAGY.' Curationz contributes digital technology and health domain expertise. The team advanced to the semifinals of the $101M longevity competition focused on reversing biological age by 10–20 years.
  • Dentsu Inc. (株式会社電通)coreStrategic or Co-development Partner · 28 November 2025Dentsu Inc. joined 'Team 10 years Rewind with AUTOPHAGY' for the XPRIZE Healthspan competition, contributing to the team's outreach and industrialization efforts for autophagy-based longevity solutions.
  • Medical Corporation Sogakai (銀座アイグラッドクリニック / 医療法人社団創雅会)majorStrategic or Co-development Partner · 1 September 2024AutoPhagyGO signed an MOU with Medical Corporation Sogakai (operator of Ginza IGrad Clinic) to jointly develop and promote new doctor's cosmetics leveraging autophagy technology, aiming to contribute to a healthy longevity society through autophagy technology social implementation.
  • Japanese Autophagy Consortium (了一般社团法人 日本オートファジーコンソーシアム)majorStrategic or Co-development Partner · 28 August 2024APGO is a participating member and co-organizer of the Japan Autophagy Consortium. CEO Miwako Ishido served as Representative Director (2020–2023) and continues as Director (2024–present). APGO co-hosts consortium symposiums and events.
  • Curationz Co., Ltd. (MOU)coreStrategic or Co-development Partner · 31 July 2024MOU signed for 'Proactive AgeTech' — combining cell science with digital technology to develop solutions that effectively suppress and restore cellular aging. Partnership centered on XPRIZE HEALTHSPAN competition entry.
  • ORGASIS Corp. (Korea)secondaryStrategic or Co-development Partner · 22 March 2024AutoPhagyGO signed an MOU with Korean venture company ORGASIS Corp. to strengthen and expand R&D capabilities. The partnership focuses on collaborative research in autophagy-related drug discovery, and new material R&D in food and cosmetics fields.
  • Human Longevity Code, Inc. (ヒューマンライフコード株式会社)secondaryStrategic or Co-development Partner · 1 November 2023Joint research contract signed November 1, 2023 to evaluate the correlation between autophagy activity and the therapeutic effects of UC-MSCs (umbilical cord-derived mesenchymal stem cells) for age-related diseases, and to explore biomarkers for clinical applications.
  • Human Metabolome Technologies, Inc. (ヒューマン・メタボローム・テクノロジーズ株式会社)majorChannel Partner/ Reseller/ Distributor · 28 August 2023Business partnership agreement for exclusive distribution of autophagy activity evaluation services. HMT provides cutting-edge metabolomics analysis services and functional ingredient development support. HMT serves as the exclusive service desk for APGO's autophagy measurement offerings, leveraging HMT's extensive sales network.
  • Muroran Institute of Technology / JST COI-NEXTminorStrategic or Co-development Partner · 25 October 2022APGO participates in the JST COI-NEXT 'Regional Co-Creation Type' project led by Muroran Institute of Technology. Focus on creating new food value through the 'Asir-Toyta' (healthy diet) co-creation hub.
  • Customer Value Co-Creation Do (顧客価値共創堂)minorImplementation/ SI/ Consulting Partner · 1 March 2022Consultant services agreement to support APGO's role as an open innovation platform, helping accelerate industry adoption of autophagy research findings and sustainable enterprise value growth.
  • Japan Autophagy Consortium (第一回日本オートファジーコンソーシアム)majorStrategic or Co-development Partner · 4 February 2022APGO participates as founding member and co-organizer of the Japan Autophagy Consortium, established to promote autophagy research applications in industry and academia.
  • EUGLENA Co., Ltd. (株式会社ユーグレナ)secondaryStrategic or Co-development Partner · 13 January 2022Joint research to investigate the effects of Euglena-derived ingredients on autophagy. APGO provides autophagy measurement capabilities while Euglena provides its proprietary microalgae ingredient research.
  • ENEOS Corporation (ENEOS株式会社)secondaryStrategic or Co-development Partner · 13 January 2022Commissioned research agreement for ENEOS-developed materials and their effects on autophagy modulation. APGO conducts autophagy activity measurement for ENEOS ingredient candidates.
  • Oxford Healthspan Ltd.secondaryStrategic or Co-development Partner · 13 January 2022Collaboration to conduct autophagy activity tests in mammalian cells. Jointly aiming to leverage autophagy function for healthspan improvement through scientific validation of longevity ingredients.
  • Kumamoto University Global Natural Products Research CenterminorStrategic or Co-development Partner · 21 December 2021Joint research with Associate Professor Go Shuto of Kumamoto University to verify the effects of autophagy activation on healthspan extension. Aims to develop autophagy-activating ingredient formulations for healthy longevity.
  • Fine Co., Ltd. (株式会社ファイン)secondaryStrategic or Co-development Partner · 15 March 2021Joint research to identify ingredients that modulate autophagy activity. Target is to develop new products with preventive and improving effects on age-related symptoms.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

AutoPhagyGO competitors and assessment

Company assessment

Direct peers

  • Timeline Nutrition (Amazentis): Timeline Nutrition commercialises Mitopure (urolithin A) — the same autophagy-activating ingredient that AutoPhagyGO co-developed with Kyowa/fracora. It is the closest direct competitor on consumer autophagy supplements globally.
  • Elysium Health: US-based direct-to-consumer longevity supplements brand built on academic research (e.g., Basis with NR/NMN). Same playbook as AutoPhagyGO: science-led IP, premium branded SKUs, longevity audiences.
  • ChromaDex: Ingredient supplier (Niagen/NMN) and longevity platform with consumer and B2B channels. Comparable to AutoPhagyGO in leveraging proprietary cellular-health IP for both ingredient licensing and consumer products.
  • Human Metabolome Technologies: Japanese metabolomics services and exclusive distribution partner for AutoPhagyGO's autophagy measurement service. Operates an overlapping B2B life-science services business and accesses many of the same Japanese pharma/food clients.

Emerging players

  • Unity Biotechnology: Clinical-stage longevity biotech developing senolytics to clear senescent cells (similar mechanism logic to APGO's autophagy activation). Same fundamental 'aging as a treatable biological state' thesis, different modality.
  • Loyal for Dogs: Vet-focused longevity biotech pursuing FDA pathway for lifespan extension drugs. Highly comparable to APGO in proving that cellular-age biology can produce regulatory-grade healthspan interventions, but on the veterinary side.

Broad incumbents

  • Calico Life Sciences: Alphabet-backed longevity R&D organisation focused on aging biology and age-related disease therapeutics. Operates at vastly larger scale but pursues the same overarching goal of translating cellular maintenance mechanisms into healthspan gains.

Others

  • UHA Mikakuto: Japanese confectionery and health-foods company that is a multi-round investor, co-developer of Autophagy Habit PLATINUM, and a strategic channel partner for AutoPhagyGO products in Japan.
  • Kobayashi Pharmaceutical: Major Japanese OTC/health-goods manufacturer, second-round investor in AutoPhagyGO and co-development partner. Comparable as a Japan-headquartered health-products commercialiser that has invested behind the autophagy thesis.

Regional players

  • Euglena Co., Ltd. Japanese bio-ingredient company (microalgae/paramylon) with an active autophagy joint-research agreement with AutoPhagyGO. Comparable as a Japan-based biotech commercialising functional food ingredients with university-derived IP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

AutoPhagyGO social profiles

Digital presence

AutoPhagyGO compliance and trust

Trust signal

Compliance4 records

AutoPhagyGO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AutoPhagyGO leadership team

Management profile

Number of profiles

Profiles5 records

AutoPhagyGO funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AutoPhagyGO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AutoPhagyGO

What does AutoPhagyGO do?

AutoPhagyGO develops, brands, and sells autophagy-activating health supplements derived from Awa Bancha (a traditional fermented tea from Tokushima Prefecture), including Awa Bancha Autophagy 100 tablets and Awa Bancha Autophagy Tea. The company also provides contract autophagy activity measurement services to food, pharmaceutical, and cosmetics companies through an exclusive partnership with Human Metabolome Technologies, and engages in joint product co-development with industry partners.

Is AutoPhagyGO a public or private company?

AutoPhagyGO is a private company. It is classified as venture growth investor backed and is currently operating.

When was AutoPhagyGO founded?

AutoPhagyGO was founded in 2019. It employs 1 to 10 people.

Where is AutoPhagyGO based?

AutoPhagyGO is headquartered in Suita, Japan, in the Asia region.

How does AutoPhagyGO make money?

Three revenue lines are on record. Consumer Health Supplement Sales are the primary driver. The others are autophagy Measurement Contract Services and co-Development and Licensing (B2B).

Who are AutoPhagyGO's main competitors?

Direct peers on record are Timeline Nutrition (Amazentis), Elysium Health, ChromaDex and Human Metabolome Technologies. Emerging players are Unity Biotechnology and Loyal for Dogs. Calico Life Sciences is listed as a broad incumbent. Others are UHA Mikakuto and Kobayashi Pharmaceutical. Euglena Co., Ltd. is listed as a regional player.

Does AutoPhagyGO have an API?

No public API is recorded for AutoPhagyGO.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales